

Executive Summary

On Molecular Diagnostics Project

Project Description

In vitro diagnostics (IVD), the global market is estimated at US\$36 billion. Molecular diagnostics is the fastest segment of IVD and will be the main clinical diagnostic approach. Molecular diagnostics mainly depends on PCR technique, but the current PCR method and its improved protocols easily lead to cross contamination. Therefore, the accuracy of diagnostic results is largely compromised. Our solely-owned patented ssPCR, which integrates the merits of molecular probe and PCR, has completely solved current problem, and will bring immensurable profits to this industry.

Business Objective

Our objective is to get more than 1/3 domestic market share in the short term, and to become one of the global leading providers of molecular diagnostics products step by step, built on our technology advantages.

Market Size and Opportunity

Early diagnosis is critical for medical treatment, which accelerates the growth of molecular diagnostics. Molecular diagnostics market is estimated to reach US\$17 billion by 2010; especially in the fields of Cardiology and Tumor, where growth rate is 92% and 37% respectively. In China, although the clinical diagnostic market is only 5 billion RMB by now, its growth rate has increased by 15-20% per year. Large population and stronger health consciousness is quickly enlarging the market and will result in a rapidly rising industry.

Target Market Description

ssPCR can be applied in many fields, which will generate thousands of kinds of products for patients and potential patients, such as hepatitis, AIDS and other STD, tumor, cardiology, etc. Their incidence rates are very high, for example, in China, only the number of HBV patients and its carriers has reached 10% of the population; the number of tumor patients is increasing by 2 million every year; cardiac death is nearly 3 million. They are our main targets for early diagnosis. Meanwhile, farm and food safe tests also create us huge market capacity and commercial opportunities.

Accordingly, our molecular diagnostics products and services will be launched, tailored to market specification, on a stage-by-stage basis.

Main Products and Service

- Product: Molecular diagnostic products
Reagent kit: Tumor, Cardiology, Prepotency, Hepatitis (extend to all hematogenous infections), etc.; Fetal Bovine Serum test kit (extend to other animal and plant disease molecular test); released reagent kits according to market requirements.
- Service: Clinic Diagnostic Center to provide test service to small and middle hospital and the community, etc.

Sustainable Competitive Advantage

- Solely-owned core techniques and patents of bio industry
- Have excellent R&D and management team
- Have steady client base and good reputation
- Have high quality, low price materials
- Mature and sufficient prepared work for project operation
- Low risk, high profit margin

Management Team

Our management team is constituted of the experts who have studied and worked in USA for many years and have rich R&D and management experiences.

- Richard H. Jiang, PhD, the technology inventor and owner, founder and shareholder of Wondergen
- Zhu Weiguo, PhD, studied in Japan and USA, Doctoral Advisor of PKU
- Zheng Qinlong, PhD, CEO of a Northern Europe Company.

Fund Requirement

Venture Capital: US\$6-10 million.

The funds will be allocated to enlarge plant and facilities, lab and GMP workshop, market and sale network and clinic diagnostic center.

Return on Investment

- IPO in 3 years
- Share Buyback

Address: D302, Zhongguancun Development Building, information Road, Shangdi, Haidian District, Beijing, P.R.C.,

Tel: 86 10 8278 1561 / 8680 1736 Fax: 0086 10 8289 8212

E-mail: wondergen2000@yhao.com.cn Website: <http://www.wondergen.com>